Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04646499 · ClinicalTrials.gov registry record · NA
Feasibility of Gamma Transcranial Alternating Current Stimulation to Reduce Beta-amyloid Load and Improve Memory
A NA study of Mild Cognitive Impairment, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04646499: Completed NA study of Mild Cognitive Impairment, sponsored by University of California, San Francisco.
NCT04646499 is a NA study of Mild Cognitive Impairment that has completed, run by University of California, San Francisco. The registered enrollment target is 14 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04646499, a NA study of Mild Cognitive Impairment, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This project assessed the feasibility of transcranial alternating current stimulation in the gamma band to lower beta-amyloid load and improve memory performance.
Primary Outcome
Side effects were measured on a scale from 0 (not noticable) to 10 (not tolerable): headache, neck pain, scalp pain, tingling, itching, burning sensation, increased sleepiness, trouble concentrating, acute mood change, and phosphenes. Average rating across all measures reported as indicator of side effects.
Conditions Studied
Interventions
- DEVICE Transcranial alternating current stimulation
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-01-18 |
| Est. Completion | 2022-05-31 |
| Phase | NA |
What the finished NCT04646499 record still lists
NCT04646499 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which Transcranial alternating current stimulation is the first listed.
NCT04646499 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04646499 about?
NCT04646499 is a clinical study titled "Feasibility of Gamma Transcranial Alternating Current Stimulation to Reduce Beta-amyloid Load and Improve Memory". This project assessed the feasibility of transcranial alternating current stimulation in the gamma band to lower beta-amyloid load and improve memory performance.
What is the current status of trial NCT04646499?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2021-01-18. Estimated completion is 2022-05-31.
What conditions does trial NCT04646499 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment.
What interventions are being tested in trial NCT04646499?
The interventions under investigation include: Transcranial alternating current stimulation (DEVICE).
Who is sponsoring clinical trial NCT04646499?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04646499 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04646499's enrollment target sits among peer trials
14 194th of 205 higher than 11 of 205 other Mild Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Dual Task Perturbation Training for OAwMCI
RECRUITING · NA
-
Impact of Intensive Computerized Cognitive Training
RECRUITING · NA
-
Multimodal Investigation of Neural Plasticity
RECRUITING · NA
-
GAMES Intervention in MCI (Mild Cognitive Impairment)
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy